Annexon (ANNX) Set to Release Quarterly Earnings on Monday

Annexon (NASDAQ:ANNX) is anticipated to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $3.50 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). On average, analysts expect Annexon to post ($1.05) EPS for the current fiscal year and ($0.84) EPS for the next fiscal year.

Annexon Price Performance

Shares of ANNX stock opened at $4.05 on Monday. Annexon has a 12-month low of $2.54 and a 12-month high of $7.18. The company has a market capitalization of $767.80 million, a PE ratio of -3.49 and a beta of 1.43. The firm has a 50 day moving average price of $4.20 and a two-hundred day moving average price of $5.23.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Annexon in a report on Monday, July 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Monday, July 13th. Needham & Company LLC lifted their price objective on shares of Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Citizens Jmp upgraded Annexon from an “underperform” rating to a “market perform” rating in a research note on Thursday, August 13th. Finally, Citigroup started coverage on Annexon in a research note on Tuesday, July 21st. They issued a “market underperform” rating on the stock. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $15.29.

Insider Buying and Selling

In other Annexon news, CEO Douglas Love bought 26,065 shares of Annexon stock in a transaction on Thursday, September 24th. The shares were purchased at an average cost of $3.83 per share, with a total value of $99,828.95. Following the acquisition, the chief executive officer directly owned 390,476 shares of the company’s stock, valued at $1,495,523.08. The trade was a 7.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.31% of the stock is currently owned by corporate insiders.

Annexon Company Profile

Annexon, Inc (NASDAQ: ANNX) is a clinical-stage biotechnology company developing therapies for diseases associated with abnormal activation of the classical complement pathway. The company’s approach is designed to selectively inhibit complement activity while preserving the immune system’s ability to perform essential functions.

Annexon’s pipeline has included ANX005, a monoclonal antibody targeting C1q, the initiating protein of the classical complement pathway. The company has evaluated ANX005 in immune-mediated and neuroinflammatory disorders, including Guillain-Barré syndrome.